Perspective Therapeutics, Inc. 8K

The 8-K furnishes an investor presentation detailing Perspective Therapeutics’ clinical-stage 212Pb radiopharmaceutical oncology pipeline, platform, and market opportunity, with key programs targeting neuroendocrine tumors, melanoma, and advanced solid tumors and key data expected in 2026.

The Form 8-K filing includes an Exhibit 99.1 investor presentation from Perspective Therapeutics, Inc. describing its next-generation 212Pb-based radiopharmaceutical oncology platform, highlighting three independent clinical-stage programs (VMT-α-NET for SSTR2+ neuroendocrine tumors, VMT01 for melanoma, and PSV359 for FAP-α–expressing advanced solid tumors) with anticipated data in 2026, along with its manufacturing, theranostic approach, intellectual property coverage across the radiopharmaceutical value chain, and the large addressable market opportunity for solid tumors. The presentation emphasizes preliminary clinical data, potential first-in-class status of the therapies, favorable safety and tumor-retention characteristics, and asserts that the company’s platform and regional manufacturing network are already built and capable of supporting further clinical and commercial advancement.

Filing Facts

CIK

728387

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-385362

Alert Tier

5